7,336 Shares in Pfizer, Inc. (PFE) Acquired by Parametrica Management Ltd

Parametrica Management Ltd acquired a new position in Pfizer, Inc. (NYSE:PFE) during the first quarter, Holdings Channel reports. The fund acquired 7,336 shares of the biopharmaceutical company’s stock, valued at approximately $251,000.

Other large investors also recently made changes to their positions in the company. D Orazio & Associates Inc. boosted its stake in shares of Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 28 shares during the period. Peregrine Asset Advisers Inc. boosted its stake in shares of Pfizer by 0.5% in the fourth quarter. Peregrine Asset Advisers Inc. now owns 7,287 shares of the biopharmaceutical company’s stock worth $237,000 after buying an additional 33 shares during the period. Pure Financial Advisors Inc. boosted its stake in shares of Pfizer by 0.4% in the first quarter. Pure Financial Advisors Inc. now owns 22,091 shares of the biopharmaceutical company’s stock worth $756,000 after buying an additional 84 shares during the period. Alpha Windward LLC boosted its stake in shares of Pfizer by 1.1% in the first quarter. Alpha Windward LLC now owns 8,387 shares of the biopharmaceutical company’s stock worth $287,000 after buying an additional 89 shares during the period. Finally, Peachtree Investment Advisors Inc. boosted its stake in shares of Pfizer by 1.3% in the first quarter. Peachtree Investment Advisors Inc. now owns 7,516 shares of the biopharmaceutical company’s stock worth $257,000 after buying an additional 100 shares during the period. 70.82% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Shares of Pfizer, Inc. (PFE) opened at 32.77 on Monday. The company has a market cap of $195.57 billion, a price-to-earnings ratio of 27.58 and a beta of 1.02. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $37.39. The company’s 50-day moving average price is $32.88 and its 200 day moving average price is $32.99.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.67 by $0.02. The company had revenue of $12.78 billion during the quarter, compared to the consensus estimate of $13.09 billion. Pfizer had a return on equity of 23.68% and a net margin of 13.76%. The firm’s revenue for the quarter was down 1.7% compared to the same quarter last year. During the same period last year, the business posted $0.67 EPS. Equities analysts predict that Pfizer, Inc. will post $2.55 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 1st. Investors of record on Friday, May 12th were given a $0.32 dividend. The ex-dividend date was Wednesday, May 10th. This represents a $1.28 annualized dividend and a yield of 3.91%. Pfizer’s payout ratio is 108.48%.

TRADEMARK VIOLATION NOTICE: This report was first reported by Mideast Time and is owned by of Mideast Time. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.mideasttime.com/7336-shares-in-pfizer-inc-pfe-acquired-by-parametrica-management-ltd/1771868.html.

Several research analysts have weighed in on PFE shares. Morgan Stanley reiterated a “neutral” rating and set a $38.00 target price on shares of Pfizer in a report on Thursday, April 6th. Citigroup Inc. lowered Pfizer from a “neutral” rating to a “sell” rating and reduced their target price for the stock from $38.00 to $31.00 in a report on Tuesday, May 16th. Vetr lowered Pfizer from a “hold” rating to a “sell” rating and set a $33.45 target price on the stock. in a report on Thursday, March 2nd. Barclays PLC reiterated a “buy” rating and set a $38.00 target price on shares of Pfizer in a report on Wednesday, May 3rd. Finally, BMO Capital Markets reiterated a “hold” rating and set a $33.00 target price on shares of Pfizer in a report on Thursday, April 27th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and an average target price of $37.54.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “PFE”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.